Viravaxx

With new appointment, Viravaxx aims to step up a gear

Vienna, Jan 11, 2021. Austrian antiviral vaccine and immunodiagnostics specialist Viravaxx has appointed Helmut Brunar, former CEO and chairman at Axentis Pharma, as chief executive officer. Dr Brunar has broad experience in vaccines and cell therapies, having managed supply chain activities at Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine program. In his eleven years as CEO | read more »

Vienna, Jan 11, 2021. Austrian antiviral vaccine and immunodiagnostics specialist Viravaxx has appointed Helmut Brunar, former CEO and chairman at Axentis Pharma, as chief executive officer.

Dr Brunar has broad experience in vaccines and cell therapies, having managed supply chain activities at Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine program. In his eleven years as CEO of Axentis Pharma, he built a team to develop respiratory drug candidate AX-TOBRA. Viravaxx focuses its activities on hard-to-treat viral infections such as respiratory syncytial virus and rhinovirus.

The company’s lead candidate is its clinical-stage hepatitis B therapy VVX001, for therapeutic and prophylactic vaccination, which is currently in Phase II trials.

Coronavirus vaccine candidate

Viravaxx is seeking to expedite development of vaccines against COVID-19 and other infectious diseases, facilitated by microarray-based assays for whole-proteome analysis.

The company said that recent progress with its SARS-CoV-2 Interaction Assay has created a turning point, and the new appointment is aiming to push the program forward.

A collaboration with the Medical University of Vienna is seeking to exploit technology to convert non- immunogenic epitopes of surface proteins into potent immunogens.

Viravaxx aims to strengthen its position in partnerships with big pharma and biotech.

Source: http://prd.at/en/newsroom-clients/immunodiagnostics-and-vaccine-development-at-viravaxx-ag-gain-momentum/